The Primary Sclerosing Cholangitis market growth is driven by factors like increase in the prevalence of Primary Sclerosing Cholangitis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Primary Sclerosing Cholangitis market report also offers comprehensive insights into the Primary Sclerosing Cholangitis market size, share, Primary Sclerosing Cholangitis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Primary Sclerosing Cholangitis market size growth forward.
Some of the key highlights from the Primary Sclerosing Cholangitis Market Insights Report:
- Several key pharmaceutical companies, including NexMed, Pfizer, and others, are developing novel products to improve the Primary Sclerosing Cholangitis treatment outlook.
- The total Primary Sclerosing Cholangitis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Primary Sclerosing Cholangitis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Primary Sclerosing Cholangitis Market Landscape
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a rare progressive disorder characterized by inflammation, thickening, and abnormal formation of fibrous tissue (fibrosis) within the passages that carry bile from the liver (bile ducts). Both the bile ducts within the liver (intrahepatic) and outside the liver (extrahepatic) are affected, resulting in the obstruction or interruption of bile flow from the liver (cholestasis).
Do you know the treatment paradigms for different countries? Download our Primary Sclerosing Cholangitis Market Sample Report
Primary Sclerosing Cholangitis Epidemiology Segmentation
DelveInsight’s Primary Sclerosing Cholangitis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Primary Sclerosing Cholangitis historical patient pools and forecasted Primary Sclerosing Cholangitis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Primary Sclerosing Cholangitis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Primary Sclerosing Cholangitis Prevalence
- Age-Specific Primary Sclerosing Cholangitis Prevalence
- Gender-Specific Primary Sclerosing Cholangitis Prevalence
- Diagnosed and Treatable Cases of Primary Sclerosing Cholangitis
Visit for more @ Primary Sclerosing Cholangitis Epidemiological Insights
Primary Sclerosing Cholangitis Treatment Market
The Primary Sclerosing Cholangitis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis market trends by analyzing the impact of current Primary Sclerosing Cholangitis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Primary Sclerosing Cholangitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Sclerosing Cholangitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Primary Sclerosing Cholangitis market in 7MM is expected to witness a major change in the study period 2019-2032.
Primary Sclerosing Cholangitis Therapy Assessment
GS-9674: Gilead Sciences
GS-9674 (Cilofexor) is an orally active, small molecule based nonsteroidal FXR agonist. The drug is in Phase III clinical studies for the treatment of Primary sclerosing cholangitis.
IMU-838: Immunic
IMU-838 is a small molecule investigational drug (vidofludimus calcium) under development as an oral tablet formulation for the treatment PSC. The drug is in clinical studies for the treatment of Relapsing-Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Ulcerative Colitis, Crohn’s Disease, and Primary Sclerosing Cholangitis. The drug is in Phase II clinical studies for the treatment of Primary sclerosing cholangitis.
Primary Sclerosing Cholangitis Key Companies
- Gilead Sciences
- Phenex Pharmaceuticals
- HighTide Therapeutics
- Dr. Falk Pharma
- Mirum Pharmaceuticals
- Pliant Therapeutics
- NGM Biopharmaceuticals
- CymaBay Therapeutics
- Chemomab Therapeutics
For more information, visit Primary Sclerosing Cholangitis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Primary Sclerosing Cholangitis Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Primary Sclerosing Cholangitis, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Primary Sclerosing Cholangitis epidemiology in the 7MM
- Primary Sclerosing Cholangitis marketed and emerging therapies
- Primary Sclerosing Cholangitis companies
- Primary Sclerosing Cholangitis market drivers and barriers
Key Questions Answered in the Primary Sclerosing Cholangitis Market Report 2032:
- What was the Primary Sclerosing Cholangitis market share distribution in 2019, and how would it appear in 2032?
- What is the total Primary Sclerosing Cholangitis market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Primary Sclerosing Cholangitis market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Primary Sclerosing Cholangitis market projected to expand at 7MM?
Table of Contents:
1 Primary Sclerosing Cholangitis Market Key Comprehensive Insights
2 Primary Sclerosing Cholangitis Market Report Introduction
3 Competitive Intelligence Analysis for Primary Sclerosing Cholangitis
4 Primary Sclerosing Cholangitis Market Analysis Overview at a Glance
5 Executive Summary of Primary Sclerosing Cholangitis
6 Primary Sclerosing Cholangitis Epidemiology and Market Methodology
7 Primary Sclerosing Cholangitis Epidemiology and Patient Population
8 Primary Sclerosing Cholangitis Patient Journey
9 Primary Sclerosing Cholangitis Treatment Algorithm, Primary Sclerosing Cholangitis Current Treatment, and Medical Practices
10 Key Endpoints in Primary Sclerosing Cholangitis Clinical Trials
11 Primary Sclerosing Cholangitis Marketed Therapies
12 Primary Sclerosing Cholangitis Emerging Therapies
13 Primary Sclerosing Cholangitis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Primary Sclerosing Cholangitis
16 Primary Sclerosing Cholangitis Market Key Opinion Leaders Reviews
18 Primary Sclerosing Cholangitis Market Drivers
19 Primary Sclerosing Cholangitis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Primary Sclerosing Cholangitis Epidemiology 2032
DelveInsight's "Primary Sclerosing Cholangitis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Primary Sclerosing Cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Primary Sclerosing Cholangitis Pipeline 2023
"Primary Sclerosing Cholangitis Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Primary Sclerosing Cholangitis market. A detailed picture of the Primary Sclerosing Cholangitis pipeline landscape is provided, which includes the disease overview and Primary Sclerosing Cholangitis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
